Ackman, Icahn Discuss Reconciling Differences at Delivering Alpha
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Tesla acquires AI hardware company for up to $2 billion in stock
Aegis Comments on FDA 510(k) Approval of Bausch + Lomb's VICTUS (VRX)
July 17, 2014 9:56 AM EDTAegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following news earlier that the company's wholly-owned subsidiary, Bausch + Lomb, has received 510(k) clearance from the FDA for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery.
Analyst Ram Selvaraju commented, In our view, this approval demonstrates the growth potential of the Bausch + Lomb product portfolio and also showcases Valeant's continued commitment to launching new products in high-growth,... More
